A genetic test may one day predict a child’s risk of obesity in adulthood, paving the way for early interventions.

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

A plan to acquire and operate what is expected to become the world’s most powerful commercial quantum computer has been ...

From the wind farms of Jutland to the rising skyline of NEOM, Denmark and Saudi Arabia are edging toward a new phase in their ...